Ovid Therapeutics (OVID) Other financing activities (2017 - 2026)
Ovid Therapeutics' (OVID) quarterly Other financing activities came in at $59.8 million in Q1 2026, up 459923.08% YoY from N/an in Q1 2025, and down 20.36% on a QoQ basis from $75.1 million in Q4 2025.
Ovid Therapeutics (OVID) Other financing activities (2017 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 10 years of Other financing activities data on file, last reported at $59.8 million in Q1 2026.
- Quarterly Other financing activities rose 459923.08% year-over-year to $59.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.9 million (up 62846.98% YoY) and the FY2025 annual result came in at $75.1 million, changed N/A from the prior year.
- Other financing activities eased to $59.8 million in Q1 2026, from $75.1 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $75.1 million in Q4 2025 to a low of -$622000.0 in Q4 2024.
- A 5-year average of $8.5 million and a median of $74314.5 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities slumped 1984.85% — and 2026, when it soared 459923.08%.
- Tracing OVID's Other financing activities over 5 years: stood at -$43599.0 in 2022, then surged by 175.69% to $33000.0 in 2023, then tumbled by 1984.85% to -$622000.0 in 2024, then surged by 12172.03% to $75.1 million in 2025, then dropped by 20.36% to $59.8 million in 2026.
- The last three Other financing activities figures came in at $59.8 million (Q1 2026), $75.1 million (Q4 2025), and $15000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.80 Mn |
| Mar 31, 2026 | 59.80 Mn |
| Dec 31, 2025 | 75.09 Mn |
| Dec 31, 2025 | 75.09 Mn |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | -622,000.00 |
| Dec 31, 2024 | -622,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | 224,000.00 |
| Sep 30, 2023 | 224,000.00 |